I. To determine progression-free survival (PFS), determine time to relapse (TTR), disease-free survival (DFS), complete resection with no tumor within 1 mm of the resection margins (R0) rate, and overall survival (OS) of pembrolizumab when combined with radiotherapy plus carboplatin and paclitaxel.